Markwin Velders

Markwin Velders is a seasoned professional in the life sciences sector, currently serving as the Managing Director and Owner of Prime Life Science BV since January 2020, where the focus is on interim management and consultancy for technology startups. Markwin holds multiple advisory and supervisory board positions, including roles at Amarna Therapeutics B.V., Thuja Capital, and NECSTGEN. Previous experience includes serving as Vice President of Operations at Kite Pharma, where novel cancer immunotherapy products were developed, and as CEO of SomantiX B.V. Markwin's educational background includes a PhD in Molecular Immunology and a Master of Science in Biomedical Sciences from Leiden University, complemented by specialized training at the Weizmann Institute of Science.